James  Peyer net worth and biography

James Peyer Biography and Net Worth

James Peyer, Ph.D. joined our Board of Directors in 2020 and serves as Chair of the Board.  He is the CEO and Founder of Cambrian Biopharma, a Distributed Drug Discovery company developing therapeutics targeting the biology of aging (‘geroscience’). The New York-based company builds, finances, and manages biotech companies. Dr. Peyer founded Cambrian to translate laboratory breakthroughs in the extension of healthy lifespan into the clinic, predicting that the world is entering a revolution in biomedical research by targeting the root causes of aging and age-related disease. Dr. Peyer has spoken on the topic of longevity biotech and investing for The Economist, TEDx, Longevity Leaders, ETH Zurich, and the Max Planck Institute on the Biology of Aging to advance the mission of achieving widespread availability of longevity therapeutics this decade. Before his current role, James was Founder and Managing Partner at Apollo Ventures, one of the major longevity-focused venture capital firms. Apollo has deployed over $20M and raised over $50M in the first three years of operations. He led investments in Cleara Biotech, Aeovian Pharmaceuticals, and Samsara Therapeutics and served on the Board and/or in executive roles for all three companies. Prior to Apollo, James was a consultant at McKinsey & Company, earned his PhD in stem cell biology at UTSW as a National Science Foundation fellow, and received his B.A. with special honors from the University of Chicago.

How do I contact James Peyer?

The corporate mailing address for Dr. Peyer and other Sensei Biotherapeutics executives is 1405 RESEARCH BLVD SUITE 125, ROCKVILLE MD, 20850. Sensei Biotherapeutics can also be reached via phone at 240-243-8000 and via email at [email protected]. Learn More on James Peyer's contact information.

Has James Peyer been buying or selling shares of Sensei Biotherapeutics?

James Peyer has not been actively trading shares of Sensei Biotherapeutics during the last quarter. Most recently, on Wednesday, March 2nd, James Peyer bought 1,203 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $3.20 per share, with a total value of $3,849.60. Learn More on James Peyer's trading history.

Who are Sensei Biotherapeutics' active insiders?

Sensei Biotherapeutics' insider roster includes James Peyer (Director), Robert Pierce (Insider), and Thomas Ricks (Director). Learn More on Sensei Biotherapeutics' active insiders.

James Peyer Insider Trading History at Sensei Biotherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/2/2022Buy1,203$3.20$3,849.60View SEC Filing Icon  
2/28/2022Buy42$3.60$151.20View SEC Filing Icon  
2/24/2022Buy15,000$3.63$54,450.00View SEC Filing Icon  
2/17/2022Buy4,949$4.17$20,637.33View SEC Filing Icon  
2/10/2022Buy5,000$4.58$22,900.00View SEC Filing Icon  
2/4/2022Buy2,500$4.45$11,125.00View SEC Filing Icon  
1/28/2022Buy8,900$4.22$37,558.00View SEC Filing Icon  
1/26/2022Buy29,900$4.62$138,138.00View SEC Filing Icon  
1/24/2022Buy22,707$4.69$106,495.83View SEC Filing Icon  
1/20/2022Buy20,000$5.17$103,400.00View SEC Filing Icon  
1/18/2022Buy10,000$5.08$50,800.00View SEC Filing Icon  
1/13/2022Buy19,953$5.13$102,358.89View SEC Filing Icon  
1/11/2022Buy10,845$5.18$56,177.10View SEC Filing Icon  
12/28/2021Buy11,288$5.28$59,600.64View SEC Filing Icon  
12/23/2021Buy11,000$5.27$57,970.00View SEC Filing Icon  
12/17/2021Buy117$5.29$618.93View SEC Filing Icon  
4/19/2021Buy1,965$13.38$26,291.70View SEC Filing Icon  
4/7/2021Buy2,000$14.00$28,000.00View SEC Filing Icon  
3/23/2021Buy10,000$14.34$143,400.00View SEC Filing Icon  
3/8/2021Buy1,000$15.25$15,250.00View SEC Filing Icon  
2/23/2021Buy20,300$17.79$361,137.00View SEC Filing Icon  
See Full Table

James Peyer Buying and Selling Activity at Sensei Biotherapeutics

This chart shows James Peyer's buying and selling at Sensei Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sensei Biotherapeutics Company Overview

Sensei Biotherapeutics logo
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $0.45
Low: $0.42
High: $0.47

50 Day Range

MA: $0.51
Low: $0.42
High: $0.78

2 Week Range

Now: $0.45
Low: $0.38
High: $1.94

Volume

272,964 shs

Average Volume

207,448 shs

Market Capitalization

$11.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16